First-in-human Phase I study of KMO inhibitor launches in UK

Medical research

Scotland-based Kynos Therapeutics has launched a first-in-human Phase I trial of its kynurenine 3-monooxygenase (KMO) inhibitor KNS366.

The study aims to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of KNS366 in healthy adult participants. The study is being conducted at a single site in the UK. Full results from the study are expected in early 2024.

KMO plays a major role in the regulation of inflammation, acting at the interface between inflammation, immunity and metabolism, and inhibition of KMO has therapeutic potential in a range of indications.

Kynos Therapeutics founder and CSO Damian Mole said: “KMO is a target of increasing interest for the development of new medicines and it is fantastic to see our highly selective KMO inhibitor, KNS366, moving into clinical development. The data generated from the advanced analysis of biomarkers will allow measurement of KMO inhibition and the impact that has on inflammatory mechanisms important in human disease. This information will be invaluable for designing the next stage of clinical trials in patients.”

Kynos Therapeutics CEO Jonathan Savidge added: “Progressing our lead KMO inhibitor rapidly into Phase I is a major milestone for Kynos. We are not aware of any other KMO inhibitors in clinical development and look forward to generating data in humans with this first-in-class mechanism. We appreciate the support of Innovate UK for its contribution to the financing of this trial.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free